Format

Send to

Choose Destination
Eur Respir J. 2018 Oct 4;52(4). pii: 1801220. doi: 10.1183/13993003.01220-2018. Print 2018 Oct.

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.

Author information

1
Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
2
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
3
INSERM U 970 and CIC 1418, Paris, France.
4
INNOVTE, Saint Etienne, France.
5
Institut Gustave Roussy, Villejuif, France.
6
Université Paris Sud, Le Kremlin Bicetre, France.
7
Hôpital Foch, Suresnes, France.
8
Hôpital privé Arras les Bonettes, Arras, France.
9
Centre Cardiologique du Nord, Saint Denis, France.
10
Hôpital André Mignot, Versailles, France.
11
Centre Hospitalier Intercommunal de Créteil, Créteil, France.
12
CHU de Poitiers, Poitiers, France.
13
Université de Poitiers, Poitiers, France.
14
Hôpital Morvan, CHU de Brest, Brest, France.
15
Hôpital de Longjumeau, Longjumeau, France.
16
Hôpital de la Pitié Salpétrière, AP-HP, Paris, France.
17
Hôpital Cochin, AP-HP, Paris, France.
18
CHU de Strasbourg, Strasbourg, France.
19
CHU de Besançon, Besançon, France.
20
Centre hospitalier régional d'Orléans, Orléans, France.
21
Hopital Saint-Joseph, Paris, France.
22
Centre hospitalier de Compiègne, Compiègne, France.
23
Centre hospitalier régional d'Annecy, Annecy, France.
24
Institut Jean Godinot, Reims, France.
25
CHU de Tours, hôpital Bretonneux, Tours, France.
26
Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris, Paris, France.

Abstract

The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg-1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269) or control (n=280), mean±sd age was 61.6±8.9 years, 190 (34.6%) patients had stage II-III disease, and 220 (40.1%) patients received adjuvant chemotherapy. Median follow-up was 5.7 years. There was no significant difference in overall survival between groups (hazard ratio (HR) 1.24, 95% CI 0.92-1.68; p=0.17). There was no difference in the cumulative incidence of recurrence between groups (subdistribution HR 0.94, 95% CI 0.68-1.30; p=0.70).Adjuvant tinzaparin had no detectable impact on overall and recurrence-free survival of patients with completely resected stage I-IIIA NSCLC. These results do not support further clinical evaluation of LMWHs as anti-tumour agents.

Conflict of interest statement

Conflict of interest: G. Meyer reports grants and non-financial support from Leo Pharma, outside the submitted work. Conflict of interest: B. Besse has nothing to disclose. Conflict of interest: H. Doubre has nothing to disclose. Conflict of interest: A. Charles-Nelson has nothing to disclose. Conflict of interest: S. Aquilanti reports non-financial support from Leo Pharma, outside the submitted work. Conflict of interest: A. Izadifar has nothing to disclose. Conflict of interest: R. Azarian has nothing to disclose. Conflict of interest: I. Monnet has nothing to disclose. Conflict of interest: C. Lamour has nothing to disclose. Conflict of interest: R. Descourt has nothing to disclose. Conflict of interest: G. Oliviero has nothing to disclose. Conflict of interest: L. Taillade has nothing to disclose. Conflict of interest: C. Chouaid has nothing to disclose. Conflict of interest: F. Giraud has nothing to disclose. Conflict of interest: P-E. Falcoz has nothing to disclose. Conflict of interest: M-P. Revel has nothing to disclose. Conflict of interest: V. Westeel has nothing to disclose. Conflict of interest: A. Dixmier has nothing to disclose. Conflict of interest: J. Tredaniel has nothing to disclose. Conflict of interest: S. Dehette has nothing to disclose. Conflict of interest: C. Decroisette has nothing to disclose. Conflict of interest: A. Prevost has nothing to disclose. Conflict of interest: E. Pichon has nothing to disclose. Conflict of interest: E. Fabre has nothing to disclose. Conflict of interest: J-C. Soria has nothing to disclose. Conflict of interest: S. Friard has nothing to disclose. Conflict of interest: J-B. Stern has nothing to disclose. Conflict of interest: L. Jabot has nothing to disclose. Conflict of interest: G. Dennewald has nothing to disclose. Conflict of interest: G. Pavy has nothing to disclose. Conflict of interest: P. Petitpretz has nothing to disclose. Conflict of interest: J-M. Tourani has nothing to disclose. Conflict of interest: M. Alifano has nothing to disclose. Conflict of interest: Dr. Chatellier has nothing to disclose. Conflict of interest: P. Girard reports personal fees and non-financial support from Leo Pharma, outside the submitted work.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center